SCHEDULE 13D: Pembroke & Partners and Robert J. Eide Disclose Significant Stake in Matinas BioPharma, Eyeing Strategic Influence and Board Representation

Pembroke & Partners LLC and Robert J. Eide have disclosed a significant beneficial ownership stake in Matinas BioPharma Holdings, Inc., acquiring preferred stock and warrants in a private placement, with intentions to actively engage with management and potentially seek board representation.

Summary

• Pembroke & Partners LLC and Robert J. Eide (Reporting Persons) have filed a Schedule 13D, disclosing their beneficial ownership in Matinas BioPharma Holdings, Inc.
• Pembroke purchased 492 shares of Series C Convertible Preferred Stock and Warrants for $492,000, convertible into up to 839,531 shares of Common Stock and exercisable for up to 1,679,182 shares of Common Stock, respectively.
• Robert J. Eide also purchased 1,500 shares of Common Stock for $5,000 prior to this transaction.
• The Issuer conducted a private placement (the "Offering") of 3,300 shares of Preferred Stock and Warrants, with an initial closing on February 13, 2025, raising $1.65 million.
• A second closing, also for $1.65 million, is contingent upon obtaining Shareholder Approval for the issuance of the Preferred Stock and Warrants.
• Until Shareholder Approval, voting and conversion/exercise of Preferred Stock and Warrants are subject to a collective 19.99% beneficial ownership and voting cap.
• Upon Shareholder Approval, the Preferred Stock will be convertible at $0.586 per share, and Warrants exercisable at $0.6446 per share.
• The Reporting Persons, along with the Sanitam Group and Adam Stern, could collectively beneficially own approximately 62.4% of outstanding Common Stock if Shareholder Approval is obtained.
• The Purchasers are entitled to nominate one director (initially Dr. Robin Smith) to the Board if they own at least 10% fully diluted, and an additional director after the Second Closing if they own at least 30%.

Sentiment

Score: 7

Explanation: The filing indicates a significant capital infusion and strategic investment, which is generally positive for a biopharma company. However, the contingency of the second closing on shareholder approval and the potential for significant ownership changes introduce some uncertainty and potential for dilution, balancing the overall sentiment.

Positives

• Significant capital infusion for Matinas BioPharma through the private placement, with $1.65 million already received and another $1.65 million contingent on shareholder approval.
• The involvement of Pembroke & Partners LLC and Robert J. Eide, who intend to monitor and evaluate their investment, potentially leading to strategic improvements and increased shareholder value.
• Potential for enhanced corporate governance and strategic direction with the right to nominate directors to the Board, including Dr. Robin Smith.
• The investment structure, including preferred stock and warrants, provides flexibility for both the company and the investors.

Negatives

• The full capital raise and the lifting of beneficial ownership/voting caps are contingent on Shareholder Approval, introducing uncertainty.
• The current 19.99% voting and beneficial ownership limit restricts the immediate influence of the new investors until Shareholder Approval is obtained.
• The potential for a significant change in ownership structure (up to 62.4% for the group) could dilute existing shareholders if not managed effectively.
• The filing indicates a potential for activist investor behavior, including proposals for changes in capitalization, ownership structure, operations, or board representation, which could lead to internal conflicts.

Risks

• Shareholder Approval Risk: The second closing of the private placement and the full conversion/exercise rights of the Preferred Stock and Warrants are contingent on obtaining Shareholder Approval, which is not guaranteed. Failure to obtain approval would limit the capital raised and the investors' influence.
• Dilution Risk: If Shareholder Approval is obtained and the Preferred Stock and Warrants are fully converted/exercised, the beneficial ownership of the Reporting Persons and their group could reach approximately 62.4% of the outstanding Common Stock, potentially leading to significant dilution for existing shareholders.
• Voting and Ownership Caps: Until Shareholder Approval, the Reporting Persons and other holders are subject to a collective 19.99% voting and beneficial ownership cap, limiting their immediate influence and the full realization of their investment's potential.
• Activist Investor Risk: The Reporting Persons explicitly state their intent to monitor, evaluate, and potentially make proposals regarding changes in capitalization, ownership structure, operations, or board representation, which could lead to strategic shifts or potential disputes.

Future Outlook

The Reporting Persons intend to continuously monitor and evaluate their investment in Matinas BioPharma, engaging in discussions with management, the board, and other stockholders regarding the Issuer's business, operations, and future plans. They may acquire additional securities, propose changes in capitalization, ownership structure, operations, or board representation, or dispose of their holdings. A second closing of the private placement, generating an additional $1.65 million in gross proceeds, is contingent upon obtaining Shareholder Approval. Upon Shareholder Approval, the investors' voting and conversion/exercise rights will be fully realized, and they will be entitled to nominate additional directors to the Board.

Industry Context

This filing indicates a significant capital infusion into Matinas BioPharma, a common occurrence in the biotech sector where companies often rely on private placements and equity financing to fund research, development, and operations. The involvement of Pembroke & Partners and Robert J. Eide, with their stated intent to engage with management and potentially seek board representation, suggests an activist investment approach, aiming to influence strategic direction and potentially unlock shareholder value. This is a trend seen across various industries where investors take substantial stakes to drive change.

Comparison to Industry Standards

• The private placement structure, involving convertible preferred stock and warrants, is a common financing mechanism for biotech companies, especially those seeking capital without immediate public market dilution or at specific valuation points.
• The 19.99% voting and beneficial ownership cap until shareholder approval is a standard regulatory measure (e.g., NYSE American rules) to prevent immediate change of control without explicit shareholder consent.
• The right to nominate board directors based on ownership thresholds (10% for one director, 30% for an additional director) is a typical provision in significant private equity or strategic investments, aligning investor interests with corporate governance.
• The stated intent of the Reporting Persons to engage in discussions about "changes in the capitalization, ownership structure, operations or board representation" is characteristic of an activist investor strategy, similar to those employed by funds like Starboard Value or Elliott Management in other sectors, aiming to drive operational or financial improvements.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for dilution if Shareholder Approval is obtained and Preferred Stock/Warrants are fully converted/exercised, as the group's ownership could reach 62.4%. However, the capital raise could also strengthen the company's financial position, potentially benefiting long-term shareholders. The increased investor engagement and board representation could lead to strategic changes impacting shareholder value.
• Company (Matinas BioPharma): Receives a significant capital infusion ($1.65 million immediately, another $1.65 million pending approval) to fund operations. Gains strategic partners who intend to actively engage with management and the board.
• Management/Board: Will face increased scrutiny and engagement from significant new investors, potentially leading to shifts in strategic direction or operational focus. New board members will be introduced.

Next Steps

• Matinas BioPharma to seek Shareholder Approval for the issuance of the Preferred Stock and Warrants to enable the second closing and lift ownership/voting caps.
• Upon Shareholder Approval, the Issuer will proceed with the second closing of the Offering, generating an additional $1.65 million in gross proceeds.
• The Reporting Persons may engage in discussions with Matinas BioPharma's management, board, and other stockholders regarding business, operations, and future plans.
• The Reporting Persons may acquire additional securities, propose changes in capitalization, ownership structure, operations, or board representation, or dispose of their holdings.
• The Purchasers will be entitled to nominate one director (Dr. Robin Smith) to the Board, and potentially an additional director after the Second Closing.

Key Dates

Recommendation

Keywords

Matinas BioPharma Holdings Inc, Pembroke & Partners LLC, Robert J. Eide, Schedule 13D, SEC Filing, Preferred Stock, Warrants, Private Placement, Capital Raise, Shareholder Approval, Beneficial Ownership, Corporate Governance, Board Representation, Biopharma Investment, Activist Investor